PHAS vs. GOVX, ARDS, NEXI, MBIO, BCEL, SXTP, EVOK, PHIO, ARAV, and RNAZ
Should you be buying PhaseBio Pharmaceuticals stock or one of its competitors? The main competitors of PhaseBio Pharmaceuticals include GeoVax Labs (GOVX), Aridis Pharmaceuticals (ARDS), NexImmune (NEXI), Mustang Bio (MBIO), Atreca (BCEL), 60 Degrees Pharmaceuticals (SXTP), Evoke Pharma (EVOK), Phio Pharmaceuticals (PHIO), Aravive (ARAV), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical preparations" industry.
GeoVax Labs (NASDAQ:GOVX) and PhaseBio Pharmaceuticals (NASDAQ:PHAS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.
In the previous week, GeoVax Labs had 1 more articles in the media than PhaseBio Pharmaceuticals. MarketBeat recorded 1 mentions for GeoVax Labs and 0 mentions for PhaseBio Pharmaceuticals. PhaseBio Pharmaceuticals' average media sentiment score of 0.38 beat GeoVax Labs' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.
6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 49.0% of PhaseBio Pharmaceuticals shares are held by institutional investors. 4.0% of GeoVax Labs shares are held by company insiders. Comparatively, 9.9% of PhaseBio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
GeoVax Labs has higher earnings, but lower revenue than PhaseBio Pharmaceuticals. GeoVax Labs is trading at a lower price-to-earnings ratio than PhaseBio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
GeoVax Labs has a beta of 2.89, suggesting that its share price is 189% more volatile than the S&P 500. Comparatively, PhaseBio Pharmaceuticals has a beta of 2.57, suggesting that its share price is 157% more volatile than the S&P 500.
GeoVax Labs presently has a consensus price target of $120.00, indicating a potential upside of 7,900.00%.
PhaseBio Pharmaceuticals received 107 more outperform votes than GeoVax Labs when rated by MarketBeat users. However, 91.67% of users gave GeoVax Labs an outperform vote while only 61.78% of users gave PhaseBio Pharmaceuticals an outperform vote.
GeoVax Labs has a net margin of 0.00% compared to GeoVax Labs' net margin of -12,572.13%. GeoVax Labs' return on equity of 0.00% beat PhaseBio Pharmaceuticals' return on equity.
Summary
GeoVax Labs beats PhaseBio Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get PhaseBio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PhaseBio Pharmaceuticals Competitors List
Related Companies and Tools
